Capital-efficient European biotech

P3T’s innovation lies in its Triple Target Activation (TTA) technology, which activates three key anti-inflammatory targets simultaneously. Combined with AI-assisted drug design, this addresses the root cause of diseases like spondyloarthritis (SpA), offering a first-in-class, disease-modifying treatment that improves on the traditional “one drug, one target” paradigm.

P3T is at the preclinical stage. Proof of concept has been confirmed in vitro using phytochemicals that activate all three targets, and in silico using multiple AI/ML models. After very encouraging in-silico modelling results, six TTA SCMs were synthesised (15 more pending) and are in in vitro testing. P3T 4.0 is the hit-to-lead candidate and has been profiled for ADME, predicted human pharmacokinetics and liver toxicity; lead optimisation and preclinical development towards an IND filing are next.

The SpA therapeutics market is projected to grow from $7.8 billion in 2025 to $16.4 billion by 2034, at a CAGR of 8.6%, with more than 50 million people affected. P3T’s technology can address this growing market with a disease-modifying option, filling a critical gap in therapeutic alternatives.

Current treatments for SpA and related diseases focus on single-target inhibition, which may not fully address the complexity of chronic inflammation. TTA activates three targets simultaneously, providing a more comprehensive solution. Our AI-driven drug design ensures rapid optimisation and scalability, so highly effective treatments can be developed faster than with traditional methods — filling the gap of a practically non-existent second-line therapy in SpA.

P3T is raising a €1M seed round to biological proof of concept, with 12–18 months of runway: hit confirmation and lead identification in 2026, followed by a second seed of €3–5M for lead optimisation and in vivo efficacy. We are looking for biotech VCs, family offices and corporate VCs, and for a pharmaceutical partner for co-development or licensing.